Alzheimer’s disease, amnestic mild cognitive impairment, normal aging Nervous System Diseases Alzheimer disease
Conditions
Interventions
This study comprised 20 Alzheimer’s disease patients (11 males and 9 females, mean, 73.2 ± 4.49 years), 20 amnestic mild cognitive impairment patients (10 males and 10 females, mean 71.55 ± 4.77 years
Sponsors
Shanghai Jiao Tong University Affiliated Sixth People’s Hospital
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: The AD group was diagnosed according to the following criteria (McKhann et al., 1984): 1. Based on the Diagnostic and Statistical Manual of Mental Disorders IV and the National Institute of Neurological and Communicative Disorders and Stroke/Alzheimer’s Disease and Related Disorders Association criteria 2. A mini-mental state examination score of = 23 Petersen diagnostic criteria were used to determine cases of aMCI (Petersen, 2004), according to: 1. Complaints of memory impairment confirmed by others 2. Objective evidence of memory impairment, e.g., memory test (delayed story recall test) scores lower than (age- and duration-) matched healthy controls by 1.5 standard deviations 3. An overall normal level of cognitive function, i.e., impairment is less than dementia level, Clinical Dementia Rating scale point = 0.5 4. Normal daily living skills, according to the Activities of Daily Living scale, mini-mental state examination score of < 26 points In the normal control (NC) group, criteria are based on capacity for independence, normal findings on neurological examination and mini-mental state examination score of = 28 points.
Exclusion criteria
Exclusion criteria: 1. Patients with history of hypertension, diabetes, mental illness, cancer, autoimmune or other diseases, or alcohol or drug abuse 2. Hachinski Ischemic Scale scores more than 4
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Mean kurtosis measured by a 3.0T magnetic resonance scanner (MAGETOM, Verio, Siemens Healthcare, Erlangen, Germany), with a 32-channel head coil after hospitalization | — |
Secondary
| Measure | Time frame |
|---|---|
| Mean diffusion, fractional anisotropy and volume of bilateral hippocampus, measured by a 3.0T magnetic resonance scanner (MAGETOM, Verio, Siemens Healthcare, Erlangen, Germany), with a 32-channel head coil after hospitalization | — |
Countries
China
Contacts
Public ContactGuoping Song
Outcome results
None listed